Blood-based metabolic signatures in Alzheimer's disease
Authors:
Francisca A. de Leeuw,
Carel F. W. Peeters,
Maartje I. Kester,
Amy C. Harms,
Eduard A. Struys,
Thomas Hankemeier,
Herman W. T. van Vlijmen,
Sven J. van der Lee,
Cornelia M. van Duijn,
Philip Scheltens,
Ayşe Demirkan,
Mark A. van de Wiel,
Wiesje M. van der Flier,
Charlotte E. Teunissen
Abstract:
Introduction: Identification of blood-based metabolic changes might provide early and easy-to-obtain biomarkers.
Methods: We included 127 AD patients and 121 controls with CSF-biomarker-confirmed diagnosis (cut-off tau/A$β_{42}$: 0.52). Mass spectrometry platforms determined the concentrations of 53 amine, 22 organic acid, 120 lipid, and 40 oxidative stress compounds. Multiple signatures were as…
▽ More
Introduction: Identification of blood-based metabolic changes might provide early and easy-to-obtain biomarkers.
Methods: We included 127 AD patients and 121 controls with CSF-biomarker-confirmed diagnosis (cut-off tau/A$β_{42}$: 0.52). Mass spectrometry platforms determined the concentrations of 53 amine, 22 organic acid, 120 lipid, and 40 oxidative stress compounds. Multiple signatures were assessed: differential expression (nested linear models), classification (logistic regression), and regulatory (network extraction).
Results: Twenty-six metabolites were differentially expressed. Metabolites improved the classification performance of clinical variables from 74% to 79%. Network models identified 5 hubs of metabolic dysregulation: Tyrosine, glycylglycine, glutamine, lysophosphatic acid C18:2 and platelet activating factor C16:0. The metabolite network for APOE $ε$4 negative AD patients was less cohesive compared to the network for APOE $ε$4 positive AD patients.
Discussion: Multiple signatures point to various promising peripheral markers for further validation. The network differences in AD patients according to APOE genotype may reflect different pathways to AD.
△ Less
Submitted 21 September, 2017;
originally announced September 2017.
